Replies to post #252102 on Anavex Life Sciences Corp (AVXL)

[rayovacAAA]

HOW MANY PATIENTS WHERE TAKING ZINC???????????????

Not looking so good for hydrocloriquine regarding COVID-19:

https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31180-6/fulltext

We did a multinational registry analysis of the use of hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19.

[Steady_T]

Hydrocloriquine treatment without ascertaining zinc status is a wasted study.

HCQ requires a zinc supplement for most people. It is the activity of the zinc inside the cell that provides the reduction of Sars-CoV-2 replication.

The HCQ functions as an ionophore moving zinc inside the cell.

This study represents a lack on understanding of the MOA.

[XenaLives]

That paper is bogus.

The analysis of factors was simply inadequate.

Methods
We did a multinational registry analysis of the use of hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19. The registry comprised data from 671 hospitals in six continents. We included patients hospitalised between Dec 20, 2019, and April 14, 2020, with a positive laboratory finding for SARS-CoV-2. Patients who received one of the treatments of interest within 48 h of diagnosis were included in one of four treatment groups (chloroquine alone, chloroquine with a macrolide, hydroxychloroquine alone, or hydroxychloroquine with a macrolide), and patients who received none of these treatments formed the control group. Patients for whom one of the treatments of interest was initiated more than 48 h after diagnosis or while they were on mechanical ventilation, as well as patients who received remdesivir, were excluded. The main outcomes of interest were in-hospital mortality and the occurrence of de-novo ventricular arrhythmias (non-sustained or sustained ventricular tachycardia or ventricular fibrillation).

https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31180-6/fulltext

FACTORS THAT ARE INADEQUATELY ANALYZED IN THE PAPER:

Therefore, patients should be screened for G6PD deficiency before treatment with these potential hemolytic agents.

https://israeltruthtimes.blogspot.com/2020/04/coronavirus-part-vii-chabad-md-zevs.html

Background/Purpose: Hydroxychloroquine (HCQ) is frequently used to treat autoimmune diseases. The HCQ package insert and online drug information resources report an increased risk of hemolytic anemia in patients with G6PD deficiency. However, no published studies quantify this potential risk, and the genetic forms of severe G6PD enzyme deficiency are very rare in the United States. A single abstract reported a 170 chart review, finding one G6PD deficient patient on HCQ with no adverse event. Through a retrospective chart review, we aimed to quantify the percentage of G6PD deficient patients with clinically significant hemolysis attributed to HCQ.

https://acrabstracts.org/abstract/hydroxychloroquine-is-not-associated-with-hemolytic-anemia-in-glucose-6-phosphate-dehydrogenase-g6pd-deficient-patients/

Controversy enveloped the announcement by the president, especially after he indicated that chloroquine has already been approved for this use by the FDA. The agency's commissioner, Stephen Hahn, MD, quickly clarified that larger studies still need to be conducted to determine the safety and effectiveness of chloroquine for treating COVID-19. Much of the discussion that continued in the media throughout the day concerned whether the drug will truly prove effective and, if so, how long will it be until this medication gets the green light for patient use. There was also confusion as to which drug is under consideration since some reports, and the president himself, made mention of hydroxychloroquine as well. The distinction is important, as will be seen shortly.

While others are focusing on the drug effectiveness component in this debate, I am more concerned about the safety with regard to chloroquine. What I haven't seen mentioned is the contraindication for use of the drug in people who have glucose-6-phosphate dehydrogenase (G6PD) deficiency. For those who need a refresher from medical school, G6PD deficiency is an X-linked recessive genetic condition, and therefore almost always occurs in males. It is found predominantly in people of African or Mediterranean origin. As a result of mutations in the G6PD gene, the amount of G6PD is either reduced or its structure is significantly altered so that it cannot perform its usual enzymatic functions.

https://www.medpagetoday.com/infectiousdisease/covid19/85552

Pediatric
Appropriate studies performed to date have not demonstrated pediatric-specific problems that would limit the usefulness of hydroxychloroquine to prevent and treat malaria in children. However, children are more sensitive to the effects of this medicine than adults. Safety and efficacy of hydroxychloroquine to treat lupus and arthritis have not been established in children.

Geriatric
Appropriate studies performed to date have not demonstrated geriatric-specific problems that would limit the usefulness of hydroxychloroquine in the elderly. However, elderly patients are more likely to have age-related kidney problems, which may require caution and an adjustment in the dose for patients receiving this medicine.

.....

Drug Interactions
Although certain medicines should not be used together at all, in other cases two different medicines may be used together even if an interaction might occur. In these cases, your doctor may want to change the dose, or other precautions may be necessary. When you are taking this medicine, it is especially important that your healthcare professional know if you are taking any of the medicines listed below. The following interactions have been selected on the basis of their potential significance and are not necessarily all-inclusive.

Using this medicine with any of the following medicines is not recommended. Your doctor may decide not to treat you with this medication or change some of the other medicines you take.

Aurothioglucose
Bepridil
Cisapride
Dronedarone
Mesoridazine
Pimozide
Piperaquine
Saquinavir
Sparfloxacin
Terfenadine
Thioridazine
Ziprasidone
Using this medicine with any of the following medicines is usually not recommended, but may be required in some cases. If both medicines are prescribed together, your doctor may change the dose or how often you use one or both of the medicines.

Acarbose
Albiglutide
Alfuzosin
Alogliptin
Amiodarone
Amisulpride
Amitriptyline
Anagrelide
Apomorphine
Aripiprazole
Aripiprazole Lauroxil
Arsenic Trioxide
Asenapine
Astemizole
Atazanavir
Auranofin
Azithromycin
Bedaquiline
Buprenorphine
Buserelin
Canagliflozin
Ceritinib
Chloroquine
Chlorpromazine
Chlorpropamide
Cimetidine
Ciprofloxacin
Citalopram
Clarithromycin
Clofazimine
Clomipramine
Clozapine
Crizotinib
Cyclobenzaprine
Cyclosporine
Dabrafenib
Dapagliflozin
Dasatinib
Degarelix
Delamanid
Desipramine
Deslorelin
Deutetrabenazine
Disopyramide
Dofetilide
Dolasetron
Domperidone
Donepezil
Doxepin
Droperidol
Dulaglutide
Ebastine
Efavirenz
Empagliflozin
Encorafenib
Entrectinib
Eribulin
Erythromycin
Escitalopram
Exenatide
Famotidine
Felbamate
Fingolimod
Flecainide
Fluconazole
Fluoxetine
Formoterol
Foscarnet
Fosphenytoin
Galantamine
Gatifloxacin
Gemifloxacin
Glasdegib
Glimepiride
Glipizide
Glyburide
Gonadorelin
Goserelin
Granisetron
Halofantrine
Haloperidol
Histrelin
Hydroquinidine
Hydroxyzine
Ibutilide
Iloperidone
Imipramine
Inotuzumab Ozogamicin
Insulin
Insulin Aspart, Recombinant
Insulin Bovine
Insulin Degludec
Insulin Detemir
Insulin Glulisine
Insulin Lispro, Recombinant
Itraconazole
Ivabradine
Ivosidenib
Ketoconazole
Lapatinib
Lefamulin
Lenvatinib
Leuprolide
Levofloxacin
Linagliptin
Liraglutide
Lixisenatide
Lofexidine
Lumefantrine
Macimorelin
Mefloquine
Metformin
Methadone
Methotrimeprazine
Metronidazole
Mifepristone
Miglitol
Mizolastine
Moricizine
Moxifloxacin
Nafarelin
Nateglinide
Nelfinavir
Nilotinib
Norfloxacin
Octreotide
Ofloxacin
Olanzapine
Ondansetron
Osilodrostat
Osimertinib
Ozanimod
Paliperidone
Panobinostat
Papaverine
Paroxetine
Pasireotide
Pazopanib
Pentamidine
Perphenazine
Pimavanserin
Pioglitazone
Pipamperone
Pitolisant
Posaconazole
Pramlintide
Probucol
Procainamide
Prochlorperazine
Promethazine
Propafenone
Protriptyline
Quetiapine
Quinidine
Quinine
Ranolazine
Repaglinide
Ribociclib
Rilpivirine
Risperidone
Ritonavir
Rosiglitazone
Saxagliptin
Semaglutide
Sertindole
Sertraline
Sevoflurane
Siponimod
Sitagliptin
Sodium Phosphate
Sodium Phosphate, Dibasic
Sodium Phosphate, Monobasic
Solifenacin
Sorafenib
Sotalol
Sulpiride
Sultopride
Sunitinib
Tacrolimus
Tamoxifen
Telaprevir
Telavancin
Telithromycin
Tetrabenazine
Tizanidine
Tolazamide
Tolbutamide
Tolterodine
Toremifene
Trazodone
Triclabendazole
Trimipramine
Triptorelin
Vandetanib
Vardenafil
Vemurafenib
Venlafaxine
Vilanterol
Vildagliptin
Vinflunine
Voriconazole
Vorinostat
Zotepine
Zuclopenthixol
Using this medicine with any of the following medicines may cause an increased risk of certain side effects, but using both drugs may be the best treatment for you. If both medicines are prescribed together, your doctor may change the dose or how often you use one or both of the medicines.

Ampicillin
Digoxin

....

Other Medical Problems
The presence of other medical problems may affect the use of this medicine. Make sure you tell your doctor if you have any other medical problems, especially:

Allergy to 4-aminoquinoline compounds (eg, chloroquine)—Should not be used in patients with this condition.
Blood or bone marrow problems or
Diabetes or
Eye or vision problems or
Muscle problems or
Nerve problems or
Porphyria (blood disorder) or
Psoriasis (skin disease) or
Stomach or bowel problems–Use with caution. May make these conditions worse.
Glucose-6-phosphate dehydrogenase (G6PD) deficiency—May cause hemolytic anemia in patients with this condition.
Kidney disease or
Liver disease—Use with caution. The effects may be increased because of the slower removal of the medicine from the body.

https://www.mayoclinic.org/drugs-supplements/hydroxychloroquine-oral-route/before-using/drg-20064216

[bas2020]

Another flawed trial without zinc supplementation.

[McMagyar]

Why would you not include Zinc?

Your team has run it up the middle and in 699 out of 700 plays you have gained 20 yards or more, every single time..
one time the opponent held you for a loss.
Every play that you tried to pass or run to the outside has ended up in loss yardage or worse.


So The idiots running the “clinical” trials.. and I use that term to refrain from using the term I think these medical frauds deserve, decide to do every single play EXCEPT run it up the middle..
Then have the gall to say that running it up the middle doesn’t work!
And people that we call our neighbors die
needlessly... then people post their fraudulent results ... it’s disgusting..

HCQ, Zinc, Zpack.. or just try HCQ and Zinc sulphate..terrible human beings..

[ososilver]

Please take some time to research Ivermectin...

[catdaddy]

Great call on the Hydroxy article, Investor!

Not looking so good for hydrocloriquine regarding COVID-19: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31180-6/fulltext


http://www.freerepublic.com/focus/f-news/3855927/posts

Lancet launched an independent peer review of the paper but when it came time for Surgisphere to put its cards on the table, it balked:

Our independent peer reviewers informed us that Surgisphere would not transfer the full dataset, client contracts, and the full ISO audit report to their servers for analysis as such transfer would violate client agreements and confidentiality requirements. As such, our reviewers were not able to conduct an independent and private peer review and therefore notified us of their withdrawal from the peer-review process…

Based on this development, we can no longer vouch for the veracity of the primary data sources. Due to this unfortunate development, the authors request that the paper be retracted.

Last week the Guardian published a follow-up report on Dr Sapan Desai, the founder of Surgisphere and the lead author of the retracted paper. He has had dozens of other papers published over the years, all of which are now receiving additional scrutiny:

Major institutions including Stanford University, which were described as research partners on the Surgisphere website, said they were not aware of any formal relationship with the company.
A study that formed the basis of Desai’s PhD may contain doctored images, according to expert claims, and the global medical publishing company Elsevier is conducting a review of his papers published in its journals.
Claims made by Desai about his qualifications gained since his medical degree have been called into doubt, including his claims to hold two PhDs, a master’s, and affiliations with major universities and colleges. Some of these affiliations have now been removed from his website and online profiles.
It looks like Dr. Desai’s entire history is full of fraudulent claims. His Wikipedia page was flagged 10 years ago because people noticed many of the claims about him were sourced to his own website.

It was only when this guy made international news that doctors who knew better noticed there was a problem. The result is not just the retraction of one paper but at least three so far and probably many more to come. Add to that the collapse of his company and significant damage to the reputations of everyone involved, including Lancet which should never have published this in the first place.